Source:http://linkedlifedata.com/resource/pubmed/id/16515570
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2006-3-6
|
| pubmed:abstractText |
A variety of agents have emerged to treat patients with recurrent epithelial ovarian cancer (EOC). Most patients receive both topotecan (T) and liposomal doxorubicin (D); however, there are no data regarding the benefit of a sequence-D followed by T (DT) or T followed by D (TD). We identified 89 consecutive patients with recurrent EOC, who received both D and T from January 1994 to January 2004 at Memorial Hospital. We compared the duration of treatment, toxicity, and overall survival (OS) for patients who received either DT or TD. Sixty-four patients received DT, and 25 patients received TD. The groups were balanced regarding age, stage, surgical debulking, platinum sensitivity, prior therapy, and intervening drugs between D and T. Median numbers of cycles on DT and TD were seven and six, respectively (P= 0.61); there was no difference in duration based on platinum sensitivity. Removal from therapy for toxicity was similar, DT (22%) and TD (36%) (P= 0.18). Finally, there was no difference in median OS based on sequence, DT (18.28 months) and TD (17.75 months) (P= NS). Platinum sensitivity did not affect median OS based on sequence. Based on duration, toxicity, and OS there is no advantage of one sequence of D and T when treating patients with recurrent EOC.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1048-891X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
16 Suppl 1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
68-73
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:16515570-Adenocarcinoma,
pubmed-meshheading:16515570-Adult,
pubmed-meshheading:16515570-Aged,
pubmed-meshheading:16515570-Aged, 80 and over,
pubmed-meshheading:16515570-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16515570-Doxorubicin,
pubmed-meshheading:16515570-Drug Administration Schedule,
pubmed-meshheading:16515570-Drug Resistance, Neoplasm,
pubmed-meshheading:16515570-Female,
pubmed-meshheading:16515570-Humans,
pubmed-meshheading:16515570-Middle Aged,
pubmed-meshheading:16515570-Neoplasm Recurrence, Local,
pubmed-meshheading:16515570-Ovarian Neoplasms,
pubmed-meshheading:16515570-Platinum Compounds,
pubmed-meshheading:16515570-Retrospective Studies,
pubmed-meshheading:16515570-Survival Analysis,
pubmed-meshheading:16515570-Topotecan,
pubmed-meshheading:16515570-Treatment Outcome
|
| pubmed:articleTitle |
Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important?
|
| pubmed:affiliation |
Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. dupontj@mskcc.org
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|